Compound profile

CJC-1295

GHRH analog

A synthetic long-acting analog of growth-hormone-releasing hormone (GHRH), studied on its own for raising the body's own growth hormone and IGF-1, distinct from any blend.

Reviewed for accuracy · Last reviewed July 8, 2026
ClassGHRH analog
RouteSubcutaneous injection
Two formsWith DAC (long-acting) or without DAC (mod GRF 1-29)
StorageRefrigerated, ~4 weeks once mixed

Overview

CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH). Rather than supplying growth hormone directly, it signals the pituitary to release the body's own growth hormone, which in turn raises IGF-1. The key thing to understand about CJC-1295 is that it comes in two distinct forms. CJC-1295 with DAC (drug affinity complex) carries an albumin-binding group that greatly extends its half-life, so it circulates for days and is dosed only about weekly. CJC-1295 without DAC, commonly sold as mod GRF 1-29, lacks that complex, is short-acting, and is dosed far more frequently. The two are often confused, so it is worth confirming which form a given product is.

The substantial human evidence behind CJC-1295 is limited to a small early-phase pharmacokinetic study of the with-DAC form. It is not FDA-approved for any use, and any dosing described here reflects that early study or community practice rather than an established regimen. This page covers CJC-1295 on its own; for the popular CJC-1295 and Ipamorelin combination, see the dedicated stack page at /compounds/cjc-1295-ipamorelin.

Dosing

There is no approved human dose. The with-DAC form was given at 30 or 60 mcg/kg weekly or biweekly in a small Phase 1 study; the without-DAC form (mod GRF 1-29) is short-acting and dosed more frequently. CJC-1295 is not FDA-approved.

Read the full CJC-1295 dosage guide →

Side effects

Human safety data is limited. Reported effects are mostly local or fluid-related: injection-site irritation, flushing, and water retention. As a GH-raising peptide, changes in insulin sensitivity are a plausible but poorly characterized consideration.

Read the full CJC-1295 side effects guide →

Storage

Keep unmixed vials refrigerated and away from light. Once reconstituted, most research reports store CJC-1295 refrigerated for roughly 4 weeks. See the full storage & safety guide for handling and disposal basics.

FAQ

What is the difference between CJC-1295 with DAC and without DAC (mod GRF 1-29)?Both are GHRH analogs built on the same core sequence. The with-DAC version adds a drug affinity complex that binds albumin and extends its half-life to several days, so it is dosed about weekly. The without-DAC version, often called mod GRF 1-29, lacks that complex, is short-acting, and is dosed more frequently. The substantial human data covers the with-DAC form only.
Is CJC-1295 the same as the CJC-1295 and Ipamorelin stack?No. This page covers CJC-1295 on its own. Ipamorelin is a separate GH secretagogue that is often combined with CJC-1295. For that combination, see the dedicated stack page at /compounds/cjc-1295-ipamorelin.
Is CJC-1295 FDA-approved?No. CJC-1295 is not FDA-approved for any use. Its main human evidence is a small early-phase pharmacokinetic study of the with-DAC form, so it should be treated as investigational.

References

  1. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adultsJournal of Clinical Endocrinology & Metabolism · 2006 · PMID 16352683 · DOI 10.1210/jc.2005-1536
  2. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouseAmerican Journal of Physiology - Endocrinology and Metabolism · 2006 · PMID 16822960 · DOI 10.1152/ajpendo.00201.2006
Running this protocol? PepHub can log your doses and remind you.Coming soon

This page is an independent educational reference and is not medical advice, and does not indicate any approval status for any use. Talk to a doctor before starting any compound.